EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has secured distribution rights for T-cell immunotherapies in Malaysia through a partnership with Shenzhen Inno Immune Co. Ltd. This marks EUDA's second major cell therapy initiative following its April 2025 stem cell therapy distribution partnership.
The agreement, facilitated through Guangdong Key Lock Health Management Co., allows EUDA's subsidiary CK Health Plus Sdn Bhd to market and sell T-cell immunotherapies in Malaysia at USD 8,000 per treatment, significantly lower than regional market prices. Shenzhen Inno brings strong credentials including a GMP-standard cell preparation center, Peacock Plan recognition, and Sequoia Capital backing.
EUDA Health Holdings (NASDAQ: EUDA), fornitore sanitario con sede a Singapore, ha ottenuto i diritti di distribuzione per immunoterapie a base di cellule T in Malesia grazie a una partnership con Shenzhen Inno Immune Co. Ltd. Questo rappresenta la seconda importante iniziativa nell'ambito delle terapie cellulari per EUDA, dopo la collaborazione per la distribuzione di terapie con cellule staminali annunciata nell'aprile 2025.
L'accordo, realizzato tramite Guangdong Key Lock Health Management Co., consente alla controllata di EUDA, CK Health Plus Sdn Bhd, di commercializzare e vendere le immunoterapie con cellule T in Malesia a USD 8.000 per trattamento, un prezzo significativamente inferiore rispetto ai livelli di mercato regionali. Shenzhen Inno vanta solide referenze, tra cui un centro di preparazione cellulare conforme agli standard GMP, il riconoscimento del Peacock Plan e il supporto di Sequoia Capital.
EUDA Health Holdings (NASDAQ: EUDA), proveedor de salud con sede en Singapur, ha obtenido los derechos de distribución de inmunoterapias con células T en Malasia mediante una asociación con Shenzhen Inno Immune Co. Ltd. Esta es la segunda iniciativa importante de EUDA en terapias celulares, tras su acuerdo de abril de 2025 para distribuir terapias con células madre.
El acuerdo, facilitado a través de Guangdong Key Lock Health Management Co., permite a la filial de EUDA, CK Health Plus Sdn Bhd, comercializar y vender inmunoterapias con células T en Malasia a USD 8.000 por tratamiento, un precio considerablemente inferior al de los mercados regionales. Shenzhen Inno aporta credenciales destacadas, incluido un centro de preparación celular con estándares GMP, el reconocimiento Peacock Plan y el respaldo de Sequoia Capital.
EUDA Health Holdings (NASDAQ: EUDA)는 싱가포르에 본사를 둔 의료 제공업체로서 Shenzhen Inno Immune Co. Ltd.와의 파트너십을 통해 말레이시아에서 T세포 면역치료제의 유통권을 확보했습니다. 이는 2025년 4월 줄기세포 치료제 유통 파트너십에 이은 EUDA의 두 번째 주요 세포치료 사업입니다.
Guangdong Key Lock Health Management Co.의 주선으로 체결된 이번 계약으로 EUDA의 자회사 CK Health Plus Sdn Bhd는 말레이시아에서 T세포 면역치료제를 치료당 미화 8,000달러에 판매·유통할 수 있게 되었으며, 이는 지역 시장 가격보다 훨씬 낮은 수준입니다. Shenzhen Inno는 GMP 기준의 세포 준비 센터, Peacock Plan 인정, Sequoia Capital의 지원 등 강력한 이력을 갖추고 있습니다.
EUDA Health Holdings (NASDAQ: EUDA), un prestataire de santé basé à Singapour, a obtenu les droits de distribution d'immunothérapies à base de cellules T en Malaisie via un partenariat avec Shenzhen Inno Immune Co. Ltd. Il s'agit de la deuxième grande initiative de EUDA dans les thérapies cellulaires, après son partenariat de distribution de thérapies à base de cellules souches annoncé en avril 2025.
L'accord, facilité par Guangdong Key Lock Health Management Co., permet à la filiale de EUDA, CK Health Plus Sdn Bhd, de commercialiser et vendre des immunothérapies à base de cellules T en Malaisie à 8 000 USD par traitement, un tarif nettement inférieur aux prix du marché régional. Shenzhen Inno apporte des références solides, notamment un centre de préparation cellulaire conforme aux normes GMP, la reconnaissance Peacock Plan et le soutien de Sequoia Capital.
EUDA Health Holdings (NASDAQ: EUDA), ein in Singapur ansässiger Gesundheitsanbieter, hat über eine Partnerschaft mit Shenzhen Inno Immune Co. Ltd. die Vertriebsrechte für T-Zell-Immuntherapien in Malaysia gesichert. Dies ist EUDAs zweite größere Zelltherapie-Initiative nach der Vertriebsvereinbarung für Stammzelltherapien im April 2025.
Die durch Guangdong Key Lock Health Management Co. vermittelte Vereinbarung erlaubt der Tochtergesellschaft CK Health Plus Sdn Bhd von EUDA, T-Zell-Immuntherapien in Malaysia zu einem Preis von USD 8.000 pro Behandlung zu vermarkten und zu verkaufen, deutlich günstiger als die regionalen Marktpreise. Shenzhen Inno bringt starke Referenzen mit, darunter ein nach GMP-Standards arbeitendes Zellvorbereitungszentrum, die Anerkennung im Rahmen des Peacock Plans und Unterstützung durch Sequoia Capital.
- Strategic expansion into T-cell immunotherapy market with exclusive Malaysian distribution rights
- Competitive pricing at USD 8,000 per treatment, significantly below regional market rates
- Partnership with Shenzhen Inno brings access to GMP-standard facilities and Sequoia Capital-backed technology
- Builds on existing stem cell therapy portfolio, strengthening position in regenerative medicine
- Success depends on market adoption of new therapy in Malaysian market
- Potential regulatory challenges in cross-border cell therapy distribution
Insights
EUDA's strategic expansion into T-cell immunotherapy in Malaysia creates new revenue opportunities while positioning the company in the growing regenerative medicine market.
EUDA Health's acquisition of distribution rights for T-cell immunotherapies in Malaysia represents a significant strategic expansion of their cellular therapy portfolio. This marks their second major move into advanced cell therapies this year, following their April 2025 partnership in autologous stem cell therapies. The company is clearly executing a deliberate strategy to establish themselves as a player in the high-growth regenerative medicine and longevity sectors.
The partnership structure is notable - working through Keylock as an intermediary distributor rather than directly with technology developer Shenzhen Inno. This arrangement likely reduces upfront investment and regulatory hurdles while leveraging established relationships, though it may compress margins compared to a direct partnership.
The
The credibility factors highlighted for Shenzhen Inno (GMP-standard facilities, Peacock Plan recognition, Sequoia Capital backing) enhance the partnership's legitimacy and suggest the therapies meet international quality standards. For EUDA, this move diversifies their healthcare offerings beyond their current portfolio while aligning with their stated focus on non-invasive healthcare solutions. The strategic expansion positions EUDA to potentially capture market share in the growing field of personalized cellular therapies across their Asian markets.
SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China. These T-cell immunotherapies are designed to restore and rebuild the body’s natural defenses.
This marks EUDA’s second major step into advanced cell therapy this year, following its April 2025 distribution partnership with Guangdong Cell Biotech Co., Ltd., a leader in autologous stem cell therapies in China. Together, these strategic actions reflect EUDA’s accelerated push into the regenerative and longevity medicine space, reinforcing its commitment to deliver science-driven, non-invasive solutions for aging and chronic conditions.
According to the terms of the agreement, Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), a long-term strategic partner to both Shenzhen Inno and EUDA and distributor of Shenzhen Inno’s stem cell therapies and regenerative medicine, has granted CK Health Plus Sdn Bhd, a wholly-owned subsidiary of EUDA, the right to market and sell to EUDA customers in Malaysia T-cell immunotherapies provided by Shenzhen Inno in China.
The T-cell immunotherapy package will retail at USD 8,000 per treatment, which is a fraction of the traditional cost in other markets in the region. This pricing strategy reflects a clinically advanced, personalized approach to long-term immune system support while making cutting-edge immunotherapy more accessible across Malaysia by addressing the historical cost barriers that have limited access to such treatments.
Shenzhen Inno brings significant scientific and institutional backing to the partnership, including:
• A GMP-standard cell and virus preparation center ensuring pharmaceutical-grade quality
• Recognition under China’s prestigious “Peacock Plan” project for elite innovation teams
• Strategic backing from leading venture capital firm Sequoia Capital during its angel investment round
• Establishment of a Postdoctoral Innovation Practice Base to foster high-level talent development
Mr. Alfred Lim, CEO of EUDA, commented, “This strategic expansion into T-cell immunotherapy represents a pivotal moment for EUDA as we continue to diversify our healthcare portfolio and deliver innovative solutions to our customers. By working with Shenzhen Inno and Keylock, we’re offering world-class immune-enhancing therapies to Malaysians at a fraction of traditional costs, furthering our mission to transform the health and wellness landscape in the region, creating significant growth potential going forward.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Shenzhen Inno, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
FAQ
What is EUDA's new T-cell immunotherapy distribution agreement?
How does this agreement fit into EUDA's business strategy?
What are the credentials of EUDA's partner Shenzhen Inno?
How much will EUDA's T-cell immunotherapy treatment cost in Malaysia?
When did EUDA announce this T-cell immunotherapy expansion?
